Cargando…

Transient Leukopenia After Radioactive Iodine Treatment in Patients With Graves’ Disease: A Retrospective Cohort Study

CONTEXT: Radioactive (131)I (RAI) for the treatment of differentiated thyroid cancer is known to induce bone marrow suppression, which occurs approximately 1 month after treatment. However, it is unknown whether RAI therapy for Graves’ disease causes bone marrow suppression. OBJECTIVE: This study ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamashita, Kaoru, Morimoto, Satoshi, Kimura, Shihori, Seki, Yasufumi, Bokuda, Kanako, Watanabe, Daisuke, Yazaki, Tomoyo, Abe, Koichiro, Ichihara, Atsuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064043/ https://www.ncbi.nlm.nih.gov/pubmed/33928204 http://dx.doi.org/10.1210/jendso/bvab039

Ejemplares similares

Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves’ disease
por: Mizuguchi, Yuki, et al.
Publicado: (2018)

A Case of a Pregnant Woman With Primary Aldosteronism and Superimposed Preeclampsia Treated With Esaxerenone
por: Yamashita, Kaoru, et al.
Publicado: (2022)

Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
por: Seki, Yasufumi, et al.
Publicado: (2023)

THU069 Growth Hormone Secretion And Serum High-sensitivity C-reactive Protein Levels In Adult Patients With Non-functioning Pituitary Tumors
por: Seki, Yasufumi, et al.
Publicado: (2023)

Effect of Pretransplant Use of Calcimimetic on Parathyroid Function after Renal Transplantation
por: Bokuda, Kanako, et al.
Publicado: (2021)

Effect of GH Deficiency Caused by Nonfunctioning Pituitary Masses on Serum C-reactive Protein Levels
por: Seki, Yasufumi, et al.
Publicado: (2023)

ODP323 Increased Serum High-Sensitivity C-Reactive Protein Levels in Adult Growth Hormone Deficient Patients with Non-Functioning Pituitary Tumors
por: Seki, Yasufumi, et al.
Publicado: (2022)

Preeclampsia up to date—What’s going on?
por: Bokuda, Kanako, et al.
Publicado: (2023)

ODP139 Association between serum soluble (pro)renin receptor level and worsening of cardiac function in hemodialysis patients: A prospective observational study
por: Morimoto, Satoshi, et al.
Publicado: (2022)

Change in BMI after radioactive iodine ablation for graves disease
por: Chen, Melinda, et al.
Publicado: (2017)

Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease
por: Kim, Min Joo, et al.
Publicado: (2022)

Primary aldosteronism in Klinefelter’s syndrome: two cases
por: Seki, Yasufumi, et al.
Publicado: (2019)

SUN-161 Primary Aldosteronism and Klinefelter’s Syndrome: Two Cases
por: Seki, Yasufumi, et al.
Publicado: (2020)

Clinical experience with radioactive iodine in the treatment of childhood and adolescent Graves' disease
por: Cury, Adriano N, et al.
Publicado: (2012)

Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease
por: Kim, Sun Hwa, et al.
Publicado: (2013)

Chylothorax Associated with Substernal Goiter in Graves’ Disease Treated with Radioactive Iodine
por: Young Oh, Seo, et al.
Publicado: (2017)

Graves' Disease-Related Pancytopenia Improved after Radioactive Iodine Ablation
por: Hamid, Omnia A., et al.
Publicado: (2020)

Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease
por: Ze, Yuyang, et al.
Publicado: (2022)

Association between radioactive iodine uptake and neutropenia in untreated Graves’ disease
por: Yang, Qian, et al.
Publicado: (2023)

Contrast medium‐induced transient severe leukopenia
por: Hongo, Takashi, et al.
Publicado: (2017)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
por: Kinouchi, Kenichiro, et al.
Publicado: (2011)

SAT-458 Effects of Obesity and Renal Function on Pituitary Function Tests in Patients with Nonfunctioning Pituitary Tumor
por: Seki, Yasufumi, et al.
Publicado: (2019)

Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors
por: Seki, Yasufumi, et al.
Publicado: (2022)

Increased Serum High-Sensitivity C-Reactive Protein in Growth Hormone-Deficient Patients With Non-Functioning Pituitary Tumors
por: Seki, Yasufumi, et al.
Publicado: (2021)

Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease
por: Park, Se Hee, et al.
Publicado: (2017)

Elevated (Pro)renin Receptor Expression Contributes to Maintaining Aerobic Metabolism in Growth Hormone Deficiency
por: Seki, Yasufumi, et al.
Publicado: (2018)

Acute psychosis caused by hypothyroidism following radioactive iodine treatment of Graves' disease
por: Hyams, Catherine, et al.
Publicado: (2013)

Thyroid storm following radioactive iodine (RAI) therapy for pediatric graves disease
por: Rohrs, Henry J., et al.
Publicado: (2014)

A Case for Lithium Pretreatment Prior to Radioactive Iodine Ablation in Grave’s Disease
por: Thakkar, Aditi, et al.
Publicado: (2021)

FRI494 Ischemic Stroke After Radioactive Iodine Therapy In Graves Disease
por: Rave, Talia, et al.
Publicado: (2023)

Treatment of Graves’ Disease With a Combination of Low Iodine Diet and Potassium Iodide Plus Radioactive Iodine Treatment
por: Ebrahim, Ismail, et al.
Publicado: (2021)

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome
por: Bokuda, Kanako, et al.
Publicado: (2010)

Lithium Carbonate in the Treatment of Graves' Disease with ATD-Induced Hepatic Injury or Leukopenia
por: Zheng, Rendong, et al.
Publicado: (2015)

The assessment of radio-adaptive response in graves' hyperthyroidism patients following radioactive iodine uptake
por: Fazeli, Zahra, et al.
Publicado: (2018)

Predictive factors for the outcomes of Graves’ disease patients with radioactive iodine ((131)I) treatment
por: Xing, Yu-Zhuo, et al.
Publicado: (2020)

Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients
por: Hu, Rui-Ting, et al.
Publicado: (2020)

De Novo Appearance of Pre-Tibial Myxedema After Radioactive Iodine Therapy for Graves’ Disease
por: Kuriakose, Cijoy K., et al.
Publicado: (2022)

No impact of dietary iodine restriction in short term development of hypothyroidism following fixed dose radioactive iodine therapy for Graves’ disease
por: Jacob, Jubbin Jagan, et al.
Publicado: (2015)

PSAT345 Neonatal Graves (NG) Affecting 3 Newborns of a Mother Treated with Radioactive Iodine (RAI) for Graves’ Disease (GD)
por: Ali, Dalal S, et al.
Publicado: (2022)

The Incidence of Hypothyroidism Following the Radioactive Iodine Treatment of Graves’ Disease and the Predictive Factors Influencing its Development
por: Husseni, Maha Abd El-Kareem El-Sayed
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t995rp5na7ls9dbn0vp6iq1vdc